Initiation of Continuous Glucose Monitoring and Mortality in Type 2 Diabetes
Main finding · All-cause mortalityResult — go to the resultHazard ratio 0.79 95% CI 0.73–0.86Authors' conclusion
In a large national cohort, initiation of CGM was associated with lower mortality in T2D patients using insulin and indicates use of CGM may have benefits that extend beyond glucose lowering.
Study context
- Population
- Adults with T2D receiving insulin, Veterans Affairs Health Care System, 2015–2020; 94% male, mean age 66new continuous glucose monitoring (CGM) users, 1:1 matched
- Participants
- 12,729 adults
- Exposure
- CGM initiation vs no CGM
- Outcome
- All-cause mortality
- Follow-up
- 18 months
Methodological detailspropensity score-matched, 1:1 matched, national, Total follow-up 17,676 (CGM) and 17,034 (non-CGM) person-years
- Propensity score-matched
- 1:1 matched
- National
- Total follow-up 17,676 (CGM) and 17,034 (non-CGM) person-years
Main finding
As reported in the abstract
Hazard ratio
0.79
95% CI 0.73–0.86
CGM usersvs Non-CGM users
HR 0.79 (95% CI 0.73–0.86)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (CI) | |
|---|---|---|
| All-cause hospitalization | 0.91 (0.86–0.96) | |
| Cardiovascular events | 0.84 (0.73–0.96) | |
| Admissions for hyperglycemia | 0.88 (0.81–0.95) | |
| 0.512Hazard ratio (log scale) |
Mortality in sensitivity and stratified analyses
- Lower mortality risk persisted after accounting for early deaths, COVID-19, recent diabetes onset, later insulin pump or newer diabetes medication use, or stratifying by CGM use frequency, frailty index or mortality risk
- 0.83 or less (all HRs 0.83 or less; CI range 0.60-0.94)
Negative control outcomes
- No differences between CGM and non-CGM users
Original publication
Initiation of Continuous Glucose Monitoring and Mortality in Type 2 Diabetes. Diabetes Technol Ther. Published 28 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →